Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Zentiva Agrees To Buy Turkish Generics Firm

March 12, 2007 | A version of this story appeared in Volume 85, Issue 11

Prague-based Zentiva has agreed to pay roughly $600 million for a 75% stake in Turkish generic drug supplier Eczacibasi. The deal includes a clause that allows Zentiva to buy the remaining 25% in two years. Zentiva says the acquisition furthers a strategy to expand its position in Central and Eastern Europe. IMS Health projects Turkey will be among the top 10 drug markets in the world by 2010. Eczacibasi, which had sales of about $260 million in 2006, markets branded generic drugs and offers contract manufacturing of active pharmaceutical ingredients.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.